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Background: Kinase activity of cGMP-dependent, type II, protein kinase (PRKG2) is required for the proliferative to
hypertrophic transition of growth plate chondrocytes during endochondral ossification. Loss of PRKG2 function in
rodent and bovine models results in dwarfism. The objective of this study was to identify pathways regulated or
impacted by PRKG2 loss of function that may be responsible for disproportionate dwarfism at the molecular level.
Methods: Microarray technology was used to compare growth plate cartilage gene expression in dwarf versus
unaffected Angus cattle to identify putative downstream targets of PRGK2.
Results: Pathway enrichment of 1284 transcripts (nominal p < 0.05) was used to identify candidate pathways
consistent with the molecular phenotype of disproportionate dwarfism. Analysis with the DAVID pathway suite
identified differentially expressed genes that clustered in the MHC, cytochrome B, WNT, and Muc1 pathways. A
second analysis with pathway studio software identified differentially expressed genes in a host of pathways (e.g. CREB1,
P21, CTNNB1, EGFR, EP300, JUN, P53, RHOA, and SRC). As a proof of concept, we validated the differential expression of
five genes regulated by P53, including CEBPA, BRCA1, BUB1, CD58, and VDR by real-time PCR (p < 0.05).
Conclusions: Known and novel targets of PRKG2 were identified as enriched pathways in this study. This study
indicates that loss of PRKG2 function results in differential expression of P53 regulated genes as well as additional
pathways consistent with increased proliferation and apoptosis in the growth plate due to achondroplastic dwarfism.
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PRKG2 is a key regulatory kinase in the proper temporal
and spatial development of growth plate cartilage. Loss
of PRKG2 function results in a disorganized mixture of
hypertrophic and proliferative chondrocytes instead of
the highly organized columnar array observed in prop-
erly formed growth plates [1]. Mouse knockouts and
natural mutations in PRKG2 in rats and cattle exhibit
achondroplastic dwarfism [1-3]. A deletion of PRKG2 on
human chromosome 4q21 was recently associated with
growth restriction and mental retardation [4]. Thus, the
functional role of PRKG2 in growth plate development
is highly conserved across species. Based on the impact* Correspondence: jreecy@iastate.edu
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unless otherwise stated.of PRKG2 on growth plate elongation across species, it
is likely that many of the pathways regulated down-
stream of PRKG2 are also highly conserved.
Several targets of PRKG2 have been identified previously.
PRKG2 signaling regulates growth plate chondrocyte
hypertrophy and hyperplasia via SRY, sex determining re-
gion Y, −box 9 (SOX9), glycogen synthase 3 beta (GSK3b),
and additional unknown factors [2,5,6]. PRKG2 phosphor-
ylation is required for nuclear translocation of SOX9.
Phosphorylated SOX9 modulates collagen expression
from a proliferative (collagen 2, COL2) to a hypertrophic
(collagen 10, COL10) program [2]. It is currently unclear
whether PRKG2 directly or indirectly regulates SOX9
signaling [6]. Phosphorylation of GSK3b at Serine 9 by
a protein complex comprised of PRKG2 and Axin1
causes increased beta-catenin (CTNNB1) activity and
increased hypertrophy of growth plate chondrocytesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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40% rescue of skeletal growth in PRKG2−/− mice [5].
Several regulators of PRKG2 have also been identified.
Notable regulators of PRKG2 include C-type naturetic
peptide (CNP), cyclic guanosine monophosphate (cGMP)
and nitric oxide (NO). CNP regulates multiple pathways
required for proper endochondral ossification. Various
mouse crosses have demonstrated that transgenic modula-
tion of CNP can rescue mice from achondroplasia caused
by disruption of fibroblast growth factor receptor 3
(FGFR3), mitogen-activated protein kinase (MAPK), or
PRKG2 signaling [7-9]. However, no direct studies have
been performed to determine if FGFR3 and MAPK are
regulated by PRKG2. Additionally, cGMP and NO act as
upstream triggers for PRKG2 signaling. These small mole-
cules have been tied to calcium signaling, apoptosis, and
proliferation processes [10,11] as well as regulation of
MAPK, nuclear factor of kappa light polypeptide gene en-
hancer in B-cells (NF-κB), mitogen-activated protein kin-
ase 8 (JNK/ MAPK8), vascular endothelial growth factor
(VEGF), and cAMP responsive element binding protein 1
(CREB) signaling [12].
To date, no studies have dissected the role of PRKG2
regulation of global gene expression in the growth plate.
Our objective was to characterize transcriptional changes
in pathways downstream of PRKG2 in hopes of discover-
ing additional regulators responsible for the switch from
proliferative to hypertrophic growth plate development.
A secondary objective is to understand the changes in
transcriptional networks in the growth plate due to
achondroplastic dwarfism. Transcriptional profiling of
Angus PRKG2R678X/R678X (dwarf ) versus PRKG2R678X/+
(unaffected) cattle was used as a means to identify
downstream targets of PRKG2.Results
Analysis of differential expression
No differentially expressed (DE) genes were detected
across genotypes after correcting for multiple testing.
Since the statistical power to detect differences in gene
expression was limited, pathway analyses were used as
a filter to prioritize DE genes. The rationale was that
transcripts within a DE signaling pathway or biological
process were likely to be over-represented even when
all genes were not DE. A nominal p < 0.05 significance
level was used for each photomechanical transfer unit
(PMT) level to declare “significance” as a first filter for
the data. We focused on pathway analysis of the PMT
70 DE gene list, because it appeared the most valid
based on the p-value histogram. The PMT 80 and
PMT 90 gene lists were used in combined analyses
only to corroborate results from the PMT 70 DE gene
list.Summary of nominally DE genes
Using a significance level of p < 0.05, 1284 genes were
detected as DE at scanning PMT 70, 860 genes at PMT
80, and 628 genes at PMT 90. Overlap between all three
PMT levels included 180 genes. A summary of the sig-
nificant probes is provided in Additional file 1.
DAVID enrichment results are consistent with known
PRKG2 biology
The gene ontology (GO) classification of genes represented
at PMT 70 showed the greatest over-representation of
genes involved in apoptosis, cell cycle regulation, cell
death, protein modification, and phosphorylation (p < 0.01,
Family-wise false discovery rate (FWFDR) < 0.10) using
the database for annotation, visualization and integrated
discovery (DAVID) tool (Table 1). Terms over-represented
from the Panther molecular function database included:
non-receptor serine threonine protein kinase, nucleic acid
binding, transferase, protein kinase, non-motor actin and
guanyl-nucleotide exchange factor (p < 0.01, FWFDR <
0.10) (Table 2). Functionally enriched gene clusters with
statistically significant enrichment score (ES) included:
proliferation (ES = 2.9), actin cytoskeletal development
(ES = 2.25), and differentiation and apoptosis (ES = 2.17).
The Angiotensin II mediated activation of JNK Pathway
via protein tyrosine kinase 2 beta (PYK2) dependent signal-
ing pathway was over-represented in the Biocarta pathway
database (p < 0.05). Over-represented KEGG pathways in-
cluded: MAPK signaling, Adherens junction, and Glycan
structures - biosynthesis 2 (p < 0.05).
Enriched biological processes from the combined ana-
lysis, including genes from the PMT70, PMT 80 and
PMT 90 gene lists, were very similar to those found
from the PMT 70 gene list (Table 3). Notable biological
processes over-represented in this analysis include:
apoptosis, cell cycle regulation, and cell death (p < 0.005,
FWFDR < 0.10). Notably, wingless-type MMTV integra-
tion site family (WNT) signaling was over-represented
in the combined analysis (p < 0.05) (Table 4). Functional
gene clustering results were also similar to those observed
in the PMT 70 data, including clusters enriched for prolif-
eration (ES = 3.69) and differentiation and apoptosis
(ES = 3.69) (Additional file 2). Note, an ES ≥ 1.3 is
equivalent to p < 0.05. [13].
Pathway studio identifies hub genes important to
apoptosis and cell cycle
We used Pathway Studio software to search for genes
that group into pathways based on published results in
PubMed. Many pathways were differentially represented
between the two PRKG2 genotypes. For this reason, we
focused our attention on pathways relevant to the known
biological function of PRKG2. A sample of highly relevant
hub genes indentified by Pathway studio included: cAMP
Table 1 Summary of Gene Ontology (GO) biological processes over-represented in the PMT70 data (p < 0.01,
FWFDR < 0.10)
GO ID and Term # genes % total P-value Benjamini*
GO:0048468 ~ cell development 82 10.26% 0.0001 0.02
GO:0048856 ~ anatomical structure development 127 15.89% 0.0002 0.02
GO:0043170 ~macromolecule metabolic process 357 44.68% 0.0004 0.02
GO:0016043 ~ cellular component organization and biogenesis 153 19.15% 0.0004 0.02
GO:0008283 ~ cell proliferation 56 7.01% 0.0004 0.01
GO:0044238 ~ primary metabolic process 400 50.06% 0.0010 0.03
GO:0044237 ~ cellular metabolic process 399 49.94% 0.0010 0.02
GO:0019953 ~ sexual reproduction 28 3.50% 0.0011 0.02
GO:0007275 ~multicellular organismal development 132 16.52% 0.0011 0.02
GO:0048869 ~ cellular developmental process 107 13.39% 0.0011 0.02
GO:0006928 ~ cell motility 32 4.01% 0.0030 0.04
GO:0051674 ~ localization of cell 32 4.01% 0.0030 0.04
GO:0009566 ~ fertilization 9 1.13% 0.0042 0.05
GO:0016265 ~ death 53 6.63% 0.0053 0.06
GO:0009605 ~ response to external stimulus 43 5.38% 0.0056 0.06
GO:0007049 ~ cell cycle 56 7.01% 0.0056 0.06
GO:0006950 ~ response to stress 65 8.14% 0.0067 0.06
GO:0022414 ~ reproductive process 24 3.00% 0.0073 0.06
*Benjamini is a measure of family-wise false discovery rate as described by Huang da et al. [13].
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dependent kinase inhibitor 1A (CDKN1A/ P21/ Cip1), ca-
tenin (cadherin-associated protein), beta 1, 88 kDa
(CTNNB1), epidermal growth factor receptor (EGFR),
E1A binding protein p300 (EP300), jun proto-oncogene
(JUN), tumor protein P53 (P53), ras homolog family mem-
ber A (RHOA), and SRC proto-oncogene, non-receptor
tyrosine kinase (SRC). Each of these genes had many dif-
ferentially regulated genes (p < 0.05) within their pathway
across PRKG2 genotypes using the common regulators
analysis (Additional file 3). The direct regulators ana-
lysis also suggested that P21, CTNNB1, EGFR, and
JUN pathways were differentially regulated across
PRKG2 genotypes. Additional pathways/hub genes withTable 2 Summary of Panther molecular function categorie
FWFDR < 0.10)
Panther molecular function process # g
MF00213: Non-receptor serine/threonine protein kinase 188
MF00042: Nucleic acid binding 299
MF00131: Transferase 113
MF00108: Protein kinase 75
MF00262: Non-motor actin binding protein 137
MF00101: Guanyl-nucleotide exchange factor 98
*Benjamini is a measure of family-wise false discovery rate as described by Huang ddifferentially expressed target genes across genotypes are
listed in Additional file 3. A combined analysis of all dif-
ferentially expressed genes found across PMT levels iden-
tified additional target genes in the P53 pathway (n = 476
genes downstream of P53). Figure 1 shows the P53 tar-
get genes detected from the PMT 70 gene list by Path-
way Studio.
Real-time PCR results confirmed differential expression of
P53 target genes
We tested eight genes to validate their status as differen-
tially expressed, including seven genes from the P53 path-
way. The primer sequences used in real-time qPCR fors over-represented in the PMT70 data (p < 0.01,







a et al. [13].
Table 3 Summary of biological processes enriched when all three PMT are combined (p < 0.01, FWFDR < 0.10)
GO Term # genes % total P-value Benjamini*
GO:0048522 ~ positive regulation of cellular process 136 8.50% 1.85E-07 7.82E-05
GO:0048518 ~ positive regulation of biological process 149 9.31% 1.01E-07 8.51E-05
GO:0048519 ~ negative regulation of biological process 154 9.62% 4.53E-07 1.28E-04
GO:0048523 ~ negative regulation of cellular process 148 9.25% 6.73E-07 1.42E-04
GO:0006996 ~ organelle organization and biogenesis 152 9.50% 2.39E-06 4.03E-04
GO:0048731 ~ system development 207 12.94% 6.89E-06 9.69E-04
GO:0030154 ~ cell differentiation 210 13.12% 3.55E-05 4.27E-03
GO:0008219 ~ cell death 108 6.75% 4.13E-05 4.35E-03
GO:0009892 ~ negative regulation of metabolic process 64 4.00% 6.11E-05 5.71E-03
GO:0051726 ~ regulation of cell cycle 74 4.62% 7.60E-05 6.39E-03
GO:0044260 ~ cellular macromolecule metabolic process 369 23.06% 9.27E-05 7.09E-03
GO:0009893 ~ positive regulation of metabolic process 64 4.00% 1.12E-04 7.85E-03
GO:0019538 ~ protein metabolic process 381 23.81% 1.83E-04 0.012
GO:0022402 ~ cell cycle process 94 5.88% 4.13E-04 0.025
GO:0007626 ~ locomotory behavior 33 2.06% 5.76E-04 0.030
GO:0042127 ~ regulation of cell proliferation 67 4.19% 5.46E-04 0.030
GO:0044248 ~ cellular catabolic process 77 4.81% 6.41E-04 0.031
GO:0006397 ~mRNA processing 40 2.50% 7.12E-04 0.033
GO:0048513 ~ organ development 146 9.12% 8.33E-04 0.036
GO:0050790 ~ regulation of catalytic activity 64 4.00% 1.33E-03 0.050
GO:0006928 ~ cell motility 57 3.56% 1.22E-03 0.050
GO:0043067 ~ regulation of programmed cell death 70 4.38% 1.30E-03 0.051
GO:0009653 ~ anatomical structure morphogenesis 129 8.06% 1.77E-03 0.063
GO:0008380 ~ RNA splicing 34 2.12% 2.95E-03 0.095
GO:0003012 ~muscle system process 27 1.69% 3.08E-03 0.095
GO:0051641 ~ cellular localization 105 6.56% 2.85E-03 0.096
GO:0051649 ~ establishment of cellular localization 102 6.38% 3.37E-03 0.097
GO:0006730 ~ one-carbon compound metabolic process 18 1.12% 3.28E-03 0.098
*Benjamini is a measure of family-wise false discovery rate as described by Huang da et al. [13].
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seven P53 target genes were confirmed as DE (p < 0.05).
Three of these genes (breast cancer 1, early onset
(BRCA1), CCAAT/ enhancer binding protein (C/
EBP), alpha (CEBPA), and CD58 molecule (CD58))
were detected as DE using the ddCT method whileTable 4 Summary of all pathways with over-represented gene
KEGG pathway # genes
Axon guidance 29
Calcium signaling pathway 31
Glycan structures - biosynthesis 2 14
Adherens junction 16
Long-term depression 16
Wnt signaling pathway 26
*Benjamini is a measure of family-wise false discovery rate as described by Huang dtwo genes, BUB1 mitotic checkpoint serine/threonine
kinase (BUB1) and vitamin D (1,25- dihydroxyvitamin
D3) receptor (VDR), were detected as DE by difference
in natural log starting copy number (p < 0.05). Figure 2
presents the coordinated change in expression of these
five genes.lists from KEGG (p < 0.05)
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Figure 1 Enriched genes in PRKG2-null growth plate in the P53 pathway. The P53 differentially expressed gene pathway as drawn by pathway
studio software. A total of 38 target genes were identified, many of which were also identified as over-enriched for their own downstream targets
by Pathway Studio. Additional details regarding the associated targets and publications supporting these target predictions are provided in
Additional file 3.
Figure 2 Validation of DE genes in the P53 pathway. The P53 pathway genes validated as differentially expressed by quantitative real-time PCR
(p < 0.05). Transcripts BRCA1, BUB1, CEBPA, and CD58 were found to be differentially expressed using the ddCT method, while VDR was differentially
expressed when comparing the natural log (ln) starting transcript copy number between genotypes. Fold changes in gene expression are presented,
where the genotype with the lowest expression level was set to one to facilitate visualization of fold change differences.
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DAVID results indicated that specific transcripts involved
in apoptosis, cellular hypertrophy, DNA damage repair,
and proliferation are differentially enriched as a result of
bovine achondroplasia
The enrichment results from DAVID identified global
changes in gene expression related to cell development,
proliferation, and death. The most significantly enriched
GO biological process for the PMT 70 data was cell de-
velopment, likely representing genes related to hyper-
trophy and terminal differentiation. Furthermore, cell
proliferation and cell cycle genes were also identified;
likely due to the increased proliferative phenotype of
PRKG2 null (PRKG2R678X/R678X) chondrocytes. Last,
and not unexpected, were changes related to cell death
and response to stress. These changes in gene expres-
sion are likely related to apoptosis in the growth plate
due to uncoordinated development of the growth plate,
which results in the inappropriate mixing of hyper-
trophic and proliferative growth zones. A combined
analysis of differentially expressed gene lists across all of
the PMT levels resulted in similar, more statistically sig-
nificant, enrichment of transcripts for biological pro-
cesses related to PRKG2 function. Enriched biological
processes from combined PMT data include: apoptosis,
cell hypertrophy/differentiation, cell proliferation and
regulation of cell cycle, and processes related to proper
organization of the growth plate (cell motility, locomo-
tory behavior and established cell localization). WNT
and calcium signaling pathways were over-represented
in a KEGG pathway enrichment analysis using the
combined gene lists. Additionally, changes were ob-
served in glycan structure processes, likely due to the
disorganization of the growth plate in PRKG2 null in-
dividuals. A key result from the enrichment analysis
across all PMT was the detection of over-represented
WNT pathway transcripts, which was recently shown to
regulate PRKG2 [5].
The functional gene-clustering tool in DAVID identi-
fied modules of genes enriched for actin cytoskeletal
and cell motility, apoptosis, kinase/kinase function,
proliferation/ cell cycle and metal ion binding from the
PMT 70 gene list (ES > 2.9). Combining all of the dif-
ferentially expressed gene lists across PMT levels re-
sulted in similar results with the addition of DNA
damage repair (ES = 1.66) and embryonic appendage/
limb development gene clusters (ES = 1.62). The bio-
logical functions enriched in these gene clusters are
consistent with increased proliferative and altered
morphology observed in PRKG2 null (dwarf ) vs. wild-
type (unaffected) individuals. In summary, DAVID en-
richment results are consistent with known biological
functions of PRKG2 and phenotypes observed in null
animals.Pathway studio identified two known PRKG2 targets in
CTNNB1 and SRC as well as a host of other possible
down-stream targets involved in apoptosis and
proliferation
Many over-represented pathways detected by Pathway
studio appear to be involved primarily in the control of
proliferation, apoptosis or a combination of both pro-
cesses [14-22]. Gene pathways differentially expressed
between genotypes include: P21, CREB1, EP300 (p300),
EGFR, JUN, SRC, RHOA, and CTNNB1. P21 appears to
be largely inhibited or down-regulated in PRKG2 wild-
type individuals compared to PRKG2 null individuals.
JUN, CREB1, EP300, RHOA, and SRC target genes ap-
pear to be up-regulated in PRKG2-null individuals. Beta-
catenin (CTNNB1) was previously identified as a down-
stream target of PRKG2 and an important regulator of
bone growth in the WNT pathway [5]. Additionally, it
has been suggested that other regulators identified in
this study (i.e. EP300 and EGFR) interact with CTNNB1
to regulate cellular differentiation and proliferation respect-
ively [15,21]. SRC is regulated by PRKG2 mediated protein
tyrosine phosphatase, non-receptor type 6 (SHP-1) phos-
phorylation in mechanically stimulated osteoblasts [23]. In
turn, SRC acts as a mitogen by promoting cell growth
through RAS and the Raf-MEK-ERK pathways. This study
also finds a RAS homologue pathway, RHOA, to be differ-
entially represented between the PRKG2 null and un-
affected individuals.
P53 is known to regulate proliferation and apoptosis in
the growth plate
The P53 pathway is a logical candidate for PRKG2 regu-
lation because P53 is a key regulator of proliferation,
apoptosis and response to DNA damage by regulating
target gene expression [24-28]. P53 regulates critical
checkpoints in the cell cycle. Increased P53 is known to
increase P21 expression, which is essential for progres-
sion from G1 to S phase of cell cycle [28]. Notably, P21
is upregulated in a variety of achondroplasia phenotypes
in humans [29,30]. The location and time where apop-
tosis occurs in the growth plate is critical for proper long
bone growth. To allow proper proliferation of chondro-
cytes, P53 is down regulated in the resting zone to pre-
vent apoptosis [31]. At the same time, apoptosis is
required for deposition of new bone at the epiphyseal-
metaphyseal junction to allow elongation of long bones
[32-34]. P53 induced apoptosis may be important to fa-
cilitate this process in long bone growth. Consistent with
this hypothesis, data indicates that P53 −/− mouse chon-
drocyte progenitor cells have impaired terminal differen-
tiation and enhanced proliferation as well as progression
into osteosarcoma [24,35]. Interestingly, PRKG2 is located
underneath a quantitative trait locus on mouse chromo-
some 5 for alpha-radiation induced osteosarcoma [20].
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GSK3 has been shown to regulate P53 via MDM2 proto-
oncogene (MDM2) phosphorylation, leading to down
regulation of P53 [36].
To validate the changes in P53 target gene’s expres-
sion, we confirmed five of seven P53 target genes as dif-
ferentially expressed by real-time PCR (p < 0.05). Gene
expression profiles indicated down-regulation of P53 in
PRKG2 null individuals, consistent with increased cellu-
lar proliferation. The P53 regulated transcripts BRCA1,
and VDR were confirmed as up-regulated in PRKG2 null
individuals, while BUB1, CD58, CEBPA were down-
regulated. These results indicate that PRKG2 may act to
turn on or turn off P53 either directly or indirectly. Our
microarray experiment indicated that MDM2 was signifi-
cantly (p < 0.001) up regulated in PRKG2 null individuals,
but we were unable to find more than a trend towards up-
regulation of MDM2 in PRKG2 nulls (p < 0.20). MDM2
acts as part of a feedback loop to regulate P53, first pro-
moting and then inhibiting P53 expression. No protein or
functional data was generated in this experiment to con-
firm these results.
Since MDM2 phosphorylation down regulates P53 sig-
naling, we asked if MDM2 could be phosphorylated by
PRKG2, acting as a direct target of PRKG2 regulation that
mediates P53 repression. Using the GPS software [37], we
were able to predict several PRKG2 phosphorylation sites
on both MDM2 and P53. The maximum log of odds
(LOD) score for MDM2 phosphorylation by PRKG2 was
7.0, where LOD = 1.69 is equivalent to p < 0.05. The most
significant LOD score for P53 phosphorylation by PRKG2
was 4.67. In comparison, SOX9, a known PRKG2 sub-
strate, had a PRKG2 phosphorylation site predicted with
a LOD = 9.33.
Conclusions
We identified differentially represented pathways in
growth plate cartilage due to dwarfism caused by loss of
PRKG2 function. Biological processes differentially regu-
lated due to PRKG2 loss of function based on ontology
enrichment analysis include: apoptosis, cellular differen-
tiation, organization and proliferation. Hub genes with
differentially expressed targets included: P21, CREB1,
EP300 (P300), EGFR, JUN, SRC, RHOA, CTNNB1, and
P53. Both SRC and CTNNB1 were previously identified
as downstream targets of PRKG2. We validated five of
eight DE genes from a microarray experiment by real-
time PCR, including five P53 regulated genes, demon-
strating that pathway enrichment can identify truly DE
genes when no other DE genes are detected. Differential
expression of P53 target genes between PRKG2 null and
wild-type individuals may indicate another way in which
PRKG2 regulates growth plate chondrocyte proliferation
and apoptosis. Alternatively, P53 expression across PRKG2genotypes may vary as a result of cellular response to
stress caused by DNA damage and cellular death in cells
that are unable to terminally differentiate in a reactive
fashion to loss of PRKG2 function. Regardless of the cause
of P53 differential expression, the change in P53 target
gene expression is important given the role of P53 in
growth plate development and regulation of apoptosis.
These results demonstrate that important differences in
gene expression in response to or as a result of PRKG2
loss of function were identified by pathway enrichment
analysis. Identification of differentially enriched pathways
due to loss of PRKG2 function may be useful in suggesting




Dwarf (PRKG2R678X/R678X) and unaffected (PRKG2R678X/+)
calves were produced by mating a mother, daughter (car-
rier, dwarf) pair to a single carrier bull. Standard embryo
transfer methods were used to allow implantation into
surrogate mothers. More than twenty embryos were pro-
duced; however, only six survived to 60 days post-
implantation. Six calves, three from each female, were
born full term from surrogate mothers in two calving
groups. Calves within the two groups were born during
the same week and were reared and euthanized together.
Two dwarves and one unaffected individual were born in
each calving group. Each animal was genotyped to verify
the dwarf or unaffected phenotype [3]. All calf rearing, ex-
perimental procedures, tissue collection and euthanization
were carried out under the guidelines of the Iowa State
University Institutional Animal Care and Use Committee
under approved protocol number 6-04-5697-B-1.
Tissue collection
Calves were euthanized at approximately 210 days of age
during a period of rapid long bone growth [38]. Whole
growth plate was collected from the tibia bone of all the
animals and preserved using RNAlater™ (Ambion, Aus-
tin, TX). Each tibia was sliced horizontally at the growth
plate to allow cartilage pieces to be removed using a
sterile razor blade. Extra care was taken to avoid harvest
of bone marrow and osteoblasts by leaving a thin layer
of growth plate on the bone epiphysis and diaphysis.
Samples were archived at - 80°C until processed for
RNA isolation.
RNA isolation
RNA was isolated from growth plate cartilage using
TRIzol™ (Invitrogen, Carlsbad, CA). A mass of 0.15 to
0.20 g of growth plate cartilage was placed into a sterile
Petri dish with one milliliter (ml) of TRIzol™. Next, each
sample was diced into a slurry using a sterile scalpel.
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in a total volume of 6 ml TRIzol™. Sample yield was mea-
sured by spectrophotometer. These initial RNA yield
values were used to estimate how much purified RNA
could be eluted by column purification (Qiagen, Valencia,
CA). Column purified RNA was stored at - 80°C for future
use.
Microarray analysis
An Oligonucleotide 70 mer microarray created by the
bovine microarray consortium was used to assay the ex-
pression of approximately 24,000 transcripts [39]. Slides
were UV cross-linked prior to each hybridization. Syn-
thesis of cDNA was carried out using Superscript II re-
verse transcriptase (Invitrogen, Carlsbad, CA) along with
the Genisphere 3DNA 350 HS kit components (Geni-
sphere, Hatfield, PA). Unaffected animals, PRKG2R678X/+,
were compared within calving group to each of the two
dwarf, PRKG2R678X/R678X, calves, resulting in two micro-
arrays per calving group. Cy 3 and Cy 5 dyes were used
for differential display of cDNA binding between geno-
type treatments to the array. Dye swapping was used for
genotype comparisons to account for differential dye in-
corporation. A total of four microarrays were hybridized
to compare PRKG2R678X/R678X and PRKG2R678X/+ animals
using the Genisphere kit. Microarrays were hybridized
using GE Healthcare's Lucidea SlidePro hybridization
oven (General Electric Healthcare, Piscataway, NJ) at the
Iowa State University DNA facility according to manufac-
turer’s protocol. All microarray data was submitted to
NCBI GEO under accession number GSE31627.
Scanning
Hybridized slides were scanned for visualization of Cy 3
and Cy 5 signal using a Pro Scan Array HT scanner at
the microarray facility within the Iowa State University,
Plant Sciences Institute. Slides were scanned at three dif-
ferent laser PMT intensities, 70, 80 and 90 PMT, to ac-
count for high and low expression levels of various
transcripts [40] as different genes will appear as
expressed or not expressed at the different PMT levels.
Images were analyzed to obtain raw signal intensities
and localized background signals with Imagene 5.1 soft-
ware. Text files were produced for each slide channel for
statistical analysis.
Statistical analysis
Image files were normalized by channel to correct for
background, differential dye incorporation using Lowess
normalization [41], and heterogeneous variance by me-
dian centering and natural log transformation using R
scripts kindly provided by Dr. Dan Nettleton, Iowa State
University. Data were analyzed using PROC MIXED of
SAS accounting for fixed effects of the dye, genotypeand calving group. The slide was included as a random
effect. To account for random effects having an esti-
mated variance of zero, we used the Kenworth-Rodgers
correction. Multiple testing corrections were made by
calculating q-values to determine false discovery rate
(FDR) levels for each gene list [42].
Pathway and gene function analysis
Genes on the bovine microarray consortium 70-mer
array were annotated where annotation or BLAST ana-
lysis could not identify the gene corresponding to each
probe. We used the SWISS-PROT protein IDs to per-
form analysis of gene function and search for over-
represented gene pathways using DAVID [13,43] and
Pathway Studio (Ariande Genomics, Rockville, MD).
Gene expression analysis with DAVID identified over-
represented gene categories, genes of specific molecular
function, functional gene clusters and pathways. Path-
ways identified by DAVID were mined from the KEGG
[44] and Biocarta pathway analysis tools. The default set-
tings for EASE were used for all of these analyses. Path-
way studio was used to find specific gene pathways that
were highly represented within a gene list. Pathway stu-
dio uses a wave propagation algorithm to text mine da-
tabases (i.e. curated literature data from PubMed) for
information about groups of entities used in analysis and
tries to relate these groups back to the gene list. We
used the direct regulators (relationship between genes
on a gene list) and common regulators (identifies up-
stream regulators that have targets within a gene list)
analyses. Gene pathways were selected as differentially
represented based on the number of connections origin-
ating from a common regulator that differed between
the two genotypes.
Real-time PCR
The cDNA from growth plate cartilage was analyzed for
differential expression by replicating each sample three
times for the target and housekeeping gene in two separ-
ate plate replicates (i.e. six total replicates of both the
target and housekeeping gene) using primers listed in
Additional file 4 for the following seven P53 regulated
genes: BRCA1, BUB1 CEBPA, CD58, MDM2, PRL and
VDR. In addition, the SOX9 responsive gene, phosphate
regulating endopeptidase homolog, X-linked (PHEX), was
assayed across genotypes by real-time PCR. We used beta-
actin as our housekeeping gene. Primer template sequences
were retrieved using the 3’ human exonic sequence as a
BLAST template to find the bovine template sequence.
Genes analyzed by real-time PCR were selected based on
the Pathway Studio analysis. Eight target genes and one
house keeping gene (Beta-actin) were analyzed to deter-
mine the validity of microarray gene expression for the
P53 pathway. Primers, PMT levels, and thermocycling
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for each target and reference gene were made and evalu-
ated for linearity in amplification. All real-time PCR data
were analyzed using MyiQ™ software to check for primer
dimmer, linear amplification (BioRad; Hercules, CA).
Statistical analysis of real-time PCR
Real-time PCR data was analyzed using the delta-delta
cycle threshold (ddCt) method [45] in Proc GLM of SAS
(SAS Institute; Cary, NC). The model used to analyze
the expression data was
yijkl ¼ pi þ gij þ grk þ eijkl;
where y = ddCt (i.e. the target gene – housekeeping gene
(beta-actin) for the dwarf subtracted from the target
gene– housekeeping gene for an unaffected individual),
p = real-time plate replicate, g = genotype, gr = common
calving and rearing group, and e = error. When genes
were not detected as differentially expressed using the
ddCT method, we analyzed the difference in log starting
copy number where the copy number of each target
gene was compared against a standard curve for the
same transcript. The model used to analyze the natural
log (ln) starting copy number data was
yijkl ¼ pi þ gij þ grk þ eijkl;
where y = ln starting value of the target gene mRNA ad-
justed for ln starting value of housekeeping gene mRNA
(ln starting number target – ln starting number beta-
actin), p = real-time plate replicate, g = R678X PRKG2
genotype, gr = common calving and rearing group, and
e = error.
Additional files
Additional file 1: List of annotations for all putative DE genes and
enriched pathways. Additional file 1 contains all probe and annotation
information for the cDNA microarray used in this study. Specifically, the
data is split into worksheets by the specific analysis and annotation
information. Each work sheet contains probe IDs differentially expressed
at p<0.05 at one of three different PMT measures. SwissProt IDs are the
human or mouse IDs for the corresponding bovine transcript. Gene
names from DAVID are the corresponding gene names from Swissprot as
Swissprot IDs were used to run the DAVID analysis.
Additional file 2: Gene Ontology (GO) enrichment results. Additional
file 2 contains all GO enrichment results for the DE genes in the PMT70
and combined datasets.
Additional file 3: Pathway studio enrichment results divided by up
and down regulated genes in PRKG2 null (dwarf) animals. Additional
file 3 contains all Pathway studio pathway enrichment results. It is
divided into worksheets by the two analysis methods detecting direct or
common regulators and the entities which provide descriptions of the
curated regulators. In addition, the data is divided by which genes were
up regulated in the wild-type (PRKG2+/-) or the dwarf (PRKG2-/-)
genotypes.
Additional file 4: Primer sequences used to confirm differential
expression of P53 target genes by real-time qPCR. Additional file 4provides a table of P53 target genes and their corresponding primer
sequences used in real-time qPCR analysis.
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